Baricitinib is a Small Molecule owned by Eli Lilly and Co, and is involved in 94 clinical trials, of which 50 were completed, 39 are ongoing, and 5 are planned.

Baricitinib is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) inhibitor. JAK1 and JAK2 enzymes are critical components of signaling mechanisms. Cytokines such as interleukin-6, 12, and 23 signal through the JAK pathway and are therapeutic targets in inflammatory diseases. JAK-dependent cytokines have also been implicated in a number of inflammatory and autoimmune diseases. The drug candidate restricts the JAK1/JAK2 signaling pathway.

The revenue for Baricitinib is expected to reach a total of $16.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Baricitinib NPV Report.

Baricitinib was originated by Incyte and is currently owned by Eli Lilly and Co.

Baricitinib Overview

Baricitinib (Olumiant) is an anti-inflammatory, immunomodulating and antineoplastic agent. It is formulated as film-coated tablets for oral route of administration. Baricitinib is indicated for the treatment of rheumatoid arthritis (RA) (including the prevention of structural injury of joints) in patients with inadequate response to standard-of-care therapies. Baricitinib in combination with remdesivir is indicated for the treatment of suspected or laboratory confirmed coronavirus disease 2019 (COVID-19) in certain hospitalized adults and pediatric patients 2 years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Olumiant is indicated as a first-in-disease systemic treatment for adults with severe alopecia areata. 

Baricitinib is under development for the treatment of active primary Sjogren’s syndrome, atopic dermatitis, polymyalgia rheumatic, mild cognitive impairment, Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), giant cell arteritis, chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), stimulator of interferon genes (STING) associated vasculopathy with onset during infancy (SAVI), chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE), Nakajo-Nishimura Syndrome, Aicardi-Goutieres Syndrome (AGS), severe juvenile dermatomyositis (JDM), focal segmental glomerulosclerosis (FSGS), Human Immunodeficiency Virus (HIV) Infections (AIDS) and non-diabetic APOL1-associated chronic kidney disease due to hypertension (HTN-CKD). It acts by targeting JAK1 and JAK2. It was also under development for primary biliary cholangitis, juvenile idiopathic arthritis-associated anterior uveitis, diabetic nephropathy, psoriatic arthritis and moderate-to-severe chronic plaque psoriasis, systemic lupus erythematosus, auto inflammatory syndromes including Aicardi Goutieres syndrome.

Eli Lilly and Co Overview

Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men’s health and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.

The company reported revenues of (US Dollars) US$28,318.4 million for the fiscal year ended December 2021 (FY2021), an increase of 15.4% over FY2020. In FY2021, the company’s operating margin was 21%, compared to an operating margin of 24.7% in FY2020. In FY2021, the company recorded a net margin of 19.7%, compared to a net margin of 25.2% in FY2020. The company reported revenues of US$6,941.6 million for the third quarter ended September 2022, an increase of 7% over the previous quarter.

Quick View – Baricitinib

Report Segments
  • Innovator (NME)
Drug Name
  • Baricitinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Dermatology
  • Gastrointestinal
  • Genetic Disorders
  • Genito Urinary System And Sex Hormones
  • Immunology
  • Infectious Disease
  • Metabolic Disorders
  • Musculoskeletal Disorders
  • Ophthalmology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.